Posted On: 09/09/2014 6:07:23 PM
Post# of 30065
Now that PhenoGuard is a separate division, I'm thinking it has far greater potential as a spin-off than the diagnostics division. Once LymPro revenues start flowing, the diagnostics division may be in the plan to fund MANF development on many fronts.
A spin-off of the PhenoGuard division into a separate company has many advantages in my opinion. MANF may have provided the business model. The PG company continues to identify promising neurotrophic proteins and obtains the appropriate patents to protect the company's IP interests. Then the various researchers around the globe do most of the research, as is currently the case with MANF. The company's therapeutic division could license promising treatments from the research patent holders or the PG company could sell some IP patents to big pharma who are interested in moving certain products forward, with milestone payments to the PG company along the way.
Just one possibility based on my limited knowledge of biotech. Perhaps some with experience in the business can correct me or add to the possibilities.
A spin-off of the PhenoGuard division into a separate company has many advantages in my opinion. MANF may have provided the business model. The PG company continues to identify promising neurotrophic proteins and obtains the appropriate patents to protect the company's IP interests. Then the various researchers around the globe do most of the research, as is currently the case with MANF. The company's therapeutic division could license promising treatments from the research patent holders or the PG company could sell some IP patents to big pharma who are interested in moving certain products forward, with milestone payments to the PG company along the way.
Just one possibility based on my limited knowledge of biotech. Perhaps some with experience in the business can correct me or add to the possibilities.
(0)
(0)
